|
KMID : 0620920180500110150
|
|
Experimental & Molecular Medicine
2018 Volume.50 No. 11 p.150 ~ p.150
|
|
|
The role of FGF-2 in smoke-induced emphysema and the therapeutic potential of recombinant FGF-2 in patients with COPD
|
|
Kim You-Sun
Hong Goo-Hyeon
Kim Doh-Hyung
Kim Young-Min
Kim Yoon-Keun
Oh Yeon-Mok
Jee Young-Koo
|
|
|
Abstract
|
|
|
|
Although the positive effects of recombinant fibroblast growth factor-2 (rFGF-2) in chronic obstructive pulmonary disease (COPD) have been implicated in previous studies, knowledge of its role in COPD remains limited. The mechanism of FGF2 in a COPD mouse model and the therapeutic potential of rFGF-2 were investigated in COPD. The mechanism and protective effects of rFGF-2 were evaluated in cigarette smoke-exposed or elastase-induced COPD animal models. Inflammation was assessed in alveolar cells and lung tissues from mice. FGF-2 was decreased in the lungs of cigarette smoke-exposed mice. Intranasal use of rFGF-2 significantly reduced macrophage-dominant inflammation and alveolar destruction in the lungs. In the elastase-induced emphysema model, rFGF-2 improved regeneration of the lungs. In humans, plasma FGF-2 was decreased significantly in COPD compared with normal subjects (10 subjects, P?=?0.037). The safety and efficacy of inhaled rFGF-2 use was examined in COPD patients, along with changes in respiratory symptoms and pulmonary function. A 2-week treatment with inhaled rFGF-2 in COPD (n?=?6) resulted in significantly improved respiratory symptoms compared with baseline levels (P?
|
|
|
KEYWORD
|
|
|
Experimental models of disease, Metabolomics
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|